Study finds 20% of high-dose Brilinta patients quit on side effects; Novo touts cost-effectiveness analysis on GLP-1 med Victoza;

> A new analysis of Brilinta study data showed that about one in five heart attack patients on the highest dose of the AstraZeneca ($AZN) drug stopped taking it because of side effects. Report

> Novo Nordisk ($NVO) touted a company-funded study showing that Victoza, its GLP-1 diabetes drug, is more cost-effective than rival drugs from Sanofi ($SNY) and AstraZeneca ($AZN). Report

> The National Health Service in England published new guidance backing the use of AbbVie's ($ABBV) Humira in children with severe refractory uveitis, an inflammatory condition affecting the eye. Report

> Boehringer Ingelheim teamed up with a handful of top U.S. research institutions to develop new treatments for inflammatory bowel diseases such as Crohn's. Release

> And Finally... Allergan ($AGN), which makes Juvéderm facial fillers and other cosmetic treatments, released a survey showing that three-fourths of respondents worry that other people will misinterpret their "resting" facial expressions. Report

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.